Translate Bio, which is developing mRNA therapeutic treatments for cystic fibrosis, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The Lexington, MA-based company was founded in 2011 and plans to list on the Nasdaq under the symbol TBIO. Translate Bio filed confidentially on February 9, 2018. Citi, Leerink Partners and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
